Thursday, December 13, 2018

MissionIRNewsBreaks – Pressure BioSciences Inc. (PBIO) New Management Hire to Drive Revenue Growth, Advance Commercialization Programs


Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables and platform solutions, recently named Dr. Bradford A. Young as its senior vice president and chief commercial officer. An article discussing the company’s recent appointment reads, “Young joins the Pressure BioSciences management team with a solid entrepreneurial background and the experience of providing executive level consulting for strategic planning, product development and commercialization to various biomedical, diagnostic and pharmaceutical companies. In his new position as senior vice president and chief commercial officer, he will play a critical role in advancing the company’s commercialization programs and overall strategic planning, with a view toward establishing new and/or enhanced revenue opportunities and significant partnerships. … More specifically, Young will promote the company’s instruments, consumables and technology platforms with synergistic companies worldwide, with a goal of integrating Pressure BioSciences’ products into their offerings. These types of collaborations and partnerships could result in major volume sales, enabling the company to significantly boost its revenue.”

To view the full article, visit http://ibn.fm/mLTOf

About Pressure BioSciences Inc.

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. The company’s products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). PBIO’s primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of its pressure-based technologies in the following areas: (1) the use of its recently acquired PreEMT technology from BaroFold, Inc. to allow entry into the biologics contract research services sector, and (2) the use of its recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. For more information, visit the company’s website at www.PressureBiosciences.com.

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html